Coronavirus Notebook: EMA Starts Review Of HIPRA’s COVID-19 Vaccine, Moderna To Set Up Australian mRNA Plant
Executive Summary
There is no shortage of news relating to potential new COVID-19 treatments and vaccines. Among other things, zapnometinib, an antiviral compound being developed by German firm Atriva, has shown strong efficacy against Omicron in a Phase I study. Also, Sweden’s ISR and Iconovo have expanded their collaboration deal to accelerate the development of an inhaled COVID-19 vaccine.
You may also be interested in...
EU Boosts COVID-19 Vaccine Supplies With Moderna & HIPRA Deals
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
EMA: First Adapted COVID-19 Vaccines Expected In September
As work continues on vaccines adapted to tackle variants of SARS-CoV-2, the EU regulator says the decision-making on such products should take place at a global level.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.